My Plaque Protocol, and Why I Started a PCSK9 Inhibitor | Simon Hill, MSc

Simon Hill walks through his own coronary plaque protocol after publishing heart scans that showed a 48% drop in plaque over 16 and a half months. The same two scans analyzed by HeartFlow, Cleerly, and QAngio produced a 48% reduction, a 20% increase, and essentially no change. He explains the role of cumulative ApoB exposure, why AI plaque estimates can diverge sixfold, and how reference databases shift percentile rankings. He also discusses why he started a PCSK9 inhibitor rather than a statin and why short-interval scan results, including his own, deserve skepticism.